WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Rhea-AI Summary

WuXi STA, a subsidiary of WuXi AppTec, has opened a new large-scale manufacturing facility for oligonucleotides and peptides in Changzhou, covering 30,570 sq.ft. This facility enhances production capacity with four large-scale oligonucleotide production lines, raising synthesis run capacity from 1.9 mol to 6.0 mol. Additionally, a new 22,260 sq.ft. peptide plant introduces three new production lines, increasing Solid Phase Peptide Synthesis total reactor volume to 6,490 L. This expansion solidifies WuXi STA's position in the CRDMO market, supporting global partners in therapy development.

Positive

• Opened a new oligonucleotide and peptide manufacturing facility in Changzhou, enhancing capacity to meet growing customer demand.
• Increased oligonucleotide synthesis capacity from 1.9 mol to 6.0 mol, expanding production capability significantly.
• New peptide plant adds three production lines, boosting total reactor volume for Solid Phase Peptide Synthesis to 6,490 L.

Negative

• None.

Site Enhances New Modality CRDMO Platform Capacity for Customers

SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus. The new facility underscores WuXi STA's ongoing commitment to enhance its capacity and capability to meet the fast-growing customer needs for oligonucleotide and peptide therapeutics development and manufacturing worldwide, making more innovative therapies accessible to the patients. 

With the opening of the new 30,570 sq.ft. oligonucleotide plant, WuXi STA extends its leadership in oligonucleotide development and manufacturing worldwide, with four large-scale oligonucleotide production lines and more than 20 small- to mid-scale production lines that increase the overall manufacturing capacity of a single synthesis run from 1.9 mol to 6.0 mol.

The new 22,260 sq.ft. peptide plant features three new production lines with reactors that can accommodate up to 1,000 L, increasing WuXi STA's overall Solid Phase Peptide Synthesis (SPPS) total reactor volume to 6,490 L.

The new facility is an essential part of WuXi STA's comprehensive end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) platform for new modalities. The platform supports oligonucleotides and peptides, including novel monomers and linkers, and complex conjugates, from early discovery to development and commercial production at any scale. With this enhanced manufacturing capacity and over 850 dedicated scientists, WuXi STA's new modality CRDMO platform can better enable global partners as their projects progress to late and commercial stages.

In addition, WuXi STA offers injectable formulation development and manufacturing services, including Lipid NanoParticle technology (LNP), as well as comprehensive analytical and Chemical, Manufacturing, and Controls (CMC) dossier preparation services, which further accelerate the development of new oligonucleotide and peptide therapeutics for the market. 

"We are pleased to support our global partners in their efforts to develop new modality therapies for patients in need," said Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA. "WuXi STA is committed to enabling partners by enhancing our new modality CRDMO platform's capacity and capability to expedite the development and commercialization of more innovative therapies to benefit patients worldwide."

WuXi STA has a global network of multiple R&D and manufacturing sites across Asia, North America and Europe, including a new pharmaceutical manufacturing campus in Middletown, Delaware that is scheduled to open in 2024.

About WuXi STA

WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry with operations across Asia, North America and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers our worldwide partners efficient, flexible, and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Controls) solutions from preclinical to commercial uses. For more information, please visit http://www.STApharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-sta-opens-new-large-scale-oligonucleotide-and-peptide-manufacturing-facility-301581900.html

SOURCE WuXi AppTec

FAQ

What is the significance of WuXi STA's new facility opened in July 2022?

The new facility enhances WuXi STA's capacity for oligonucleotide and peptide manufacturing, addressing increasing customer demand and supporting the development of innovative therapies.

How does the new manufacturing facility affect WuXi STA's production capacity?

The facility increases oligonucleotide synthesis capacity from 1.9 mol to 6.0 mol and boosts peptide synthesis total reactor volume to 6,490 L.

Where is WuXi STA's new large-scale manufacturing facility located?

The new facility is located at WuXi STA's campus in Changzhou.

What types of manufacturing does WuXi STA's new facility support?

The facility supports the manufacturing of oligonucleotides and peptides, including novel monomers and linkers for complex conjugates.

What role does WuXi STA play in the CRDMO market?

WuXi STA is a leading player in the CRDMO market, providing integrated CMC solutions from preclinical to commercial stages.